Should testosterone replacement therapy be initiated in an adult woman with factor V Leiden and protein S deficiency?

Testosterone Replacement Therapy Should NOT Be Initiated in This Patient

Testosterone replacement therapy is contraindicated in an adult woman with Factor V Leiden and protein S deficiency due to the significant thrombotic risk posed by the combination of testosterone therapy and underlying thrombophilia.

Critical Safety Concerns

The combination of testosterone therapy and inherited thrombophilia creates a dangerous synergistic thrombotic risk that outweighs any potential benefits:

Testosterone-Induced Thrombosis in Thrombophilia

Research demonstrates that testosterone therapy interacts with thrombophilia to cause thrombotic events, typically occurring within 4-6 months of treatment initiation 1, 2, 3. In a case series of 42 patients who developed thrombosis after starting testosterone therapy, 39 of 40 (98%) had previously undiagnosed thrombophilia 3. Specifically:

• 31% of patients who developed osteonecrosis after testosterone therapy were Factor V Leiden heterozygotes versus only 2% of healthy controls (p=0.0003) 2
• Thrombotic events occurred at a median of 5-6 months after initiating testosterone therapy 1, 2, 3
• In 8 men who continued testosterone despite thrombotic events, second thrombotic events occurred despite adequate anticoagulation with warfarin, and 3 experienced third events 3

Mechanism of Increased Risk

Testosterone is aromatized to estradiol, and estradiol-induced thrombophilia superimposed on familial thrombophilia (Factor V Leiden and protein S deficiency in this case) creates a compounded prothrombotic state 1. This patient has two inherited thrombophilias, exponentially increasing her baseline thrombotic risk.

Guideline-Based Contraindications

Women-Specific Guidelines

The 2014 Endocrine Society Clinical Practice Guideline on androgen therapy in women explicitly states:

• "We recommend against the generalized use of testosterone by women" for most indications due to lack of clear indications and evidence of long-term safety 4
• "We recommend against making a clinical diagnosis of androgen deficiency syndrome in healthy women" because there is no well-defined syndrome 4

The 2019 Global Consensus Position Statement reinforces that:

• The only evidence-based indication for testosterone in women is postmenopausal HSDD (hypoactive sexual desire disorder) after formal biopsychosocial assessment 5
• Even for this indication, women at high cardiometabolic disease risk were excluded from randomized trials, making safety data ungeneralizable to higher-risk populations 5

Thrombophilia as a Contraindication

While testosterone guidelines for men do not explicitly list thrombophilia as an absolute contraindication, the research evidence is compelling:

• Authors recommend that "before giving testosterone, at a minimum, screening for Factor V Leiden and G20210A mutations, and Factor VIII and XI activity be carried out, to avoid unanticipated thrombosis" 1
• "Before beginning testosterone therapy, especially in men with previous history of thrombotic events, we suggest measurements be made for Factor V Leiden and Prothrombin mutations" to identify those who should not receive testosterone 3

Clinical Algorithm for This Patient

Given this patient's dual thrombophilia:

1. Do NOT initiate testosterone therapy - the thrombotic risk is unacceptable
2. If symptoms suggest androgen deficiency:
   • Evaluate for other treatable causes (thyroid dysfunction, depression, sleep disorders, medication side effects)
   • Consider non-hormonal interventions for specific symptoms
   • Refer for biopsychosocial assessment if sexual dysfunction is the primary concern
3. If thrombotic symptoms develop: Immediate anticoagulation and hematology consultation
4. Counsel the patient about the specific risks of testosterone in the setting of her thrombophilias

Important Caveats

• FDA-approved testosterone formulations for women do not exist in the United States 4, 5, 6
• Compounded "bioidentical" testosterone preparations cannot be recommended due to lack of efficacy and safety data 5
• Even if an indication existed, achieving physiologic female testosterone levels would still carry thrombotic risk in this patient with dual thrombophilia
• The combination of Factor V Leiden and protein S deficiency creates a multiplicative rather than additive thrombotic risk

The risk of life-threatening thrombosis (deep vein thrombosis, pulmonary embolism, stroke, osteonecrosis) far exceeds any potential benefit from testosterone therapy in this clinical scenario.